Loading…
Paragraf, Ltd. acquired Cardea Bio, the developer of the CRISPR-Chip graphene-based biosensor. The acquisition combines Paragraf's mass production of graphene electronics with Cardea's biosensor expertise to support CRISPR QC's gene editing analytics platform.